Robert J. Spiegel

Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Craig M. McDonald, Craig Campbell, Ricardo Erazo Torricelli et al. · The Lancet · 2017 · 446 citations · Full text

Rare Diseases, Urology, Clinical Trials +5

Ataluren treatment of patients with nonsense mutation dystrophinopathy

K. Bushby, Richard S. Finkel, Brenda Wong et al. · Muscle & Nerve · 2014 · 416 citations · Full text

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

Eitan Kerem, Michael W. Konstan, K. De Boeck et al. · The Lancet Respiratory Medicine · 2014 · 333 citations · Full text

Allergy, Placebo-controlled Phase 3, Clinical Trials +3

An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults

I T Magrath, Christopher Janus, BK Edwards et al. · Blood · 1984 · 251 citations · Full text

Direct access to serum macromolecules by intraerythrocytic malaria parasites

Bruno Pouvelle, Robert J. Spiegel, Li Li Hsiao et al. · Nature · 1991 · 219 citations

Malaria, Parasite Control, Medicine +2